Clinical Trials Directory

Trials / Completed

CompletedNCT04727021

A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy Men

Single-dose, Open-label, Randomized, 2-way Crossover Bioequivalence Study of 20 mg Granules for Oral Suspension Rivaroxaban Versus 20 mg Tablets Rivaroxaban Under Fed Condition in Healthy Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Bayer · Industry
Sex
Male
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

Researchers are looking for a better way to treat venous thromboembolic disease, also known as VTE. In people with VTE, blood clots form in the veins of the legs, groin, or arms. These clots or a piece of a clot can break free and move around the body in the blood vessels. These clots can block small blood vessels, causing other conditions like high blood pressure, heart attack, and stroke. Before people with a medical condition can take an approved treatment in a new form, researchers do trials in healthy participants. This helps them understand how the new form acts in the body and to better understand its safety. In this trial, the researchers will compare how much of the trial treatment gets into the blood when taken in 2 different forms in a small number of participants. The trial will include about 30 men who are aged 18 to 55. In this trial, there will be 2 groups of participants. The participants will take rivaroxaban in the current tablet form and in a new liquid form 1 time. This was a "crossover" trial. In a crossover trial, all the participants will take both forms of the treatments, but in a different order. During the trial, the participants will stay at their trial site 2 times for 5 days. But, the participants can be in the trial for up to about 6 weeks. During the trial, the doctors will take blood and urine samples and check the participants' heart health using an electrocardiogram (ECG) and measure the blood pressure. The participants will also answer questions about how they are feeling, if they have any medical problems, and about any medications they are taking.

Conditions

Interventions

TypeNameDescription
DRUG20 mg tablet rivaroxabanSingle oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions
DRUG20 mg rivaroxaban, granules for oral suspensionSingle oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions.

Timeline

Start date
2017-07-04
Primary completion
2017-09-04
Completion
2017-10-27
First posted
2021-01-27
Last updated
2021-01-27

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT04727021. Inclusion in this directory is not an endorsement.